| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-12-23 |
| タイトル |
|
|
タイトル |
Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Itonaga, Hidehiro
Miyazaki, Yasushi
Fujioka, Machiko
Aoki, Jun
Doki, Noriko
Nishida, Tetsuya
Fukuda, Takahiro
Uchida, Naoyuki
Ueda, Yasunori
Uehara, Yasufumi
Katayama, Yuta
Ota, Shuichi
Kawakita, Toshiro
Kato, Jun
Matsuoka, Ken-ichi
Eto, Tetsuya
Onizuka, Makoto
Ichinohe, Tatsuo
Atsuta, Yoshiko
Ishiyama, Ken
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Poor prognostic factors, such as transfusion dependency and chromosomal risk, need to be considered in the indication of allogeneic hematopoietic cell transplantation (allo-HCT) for patients harboring myelodysplastic syndromes with less than 5% marrow blasts (MDS-Lo). We analyzed the post-transplant outcomes of 1229 MDS-Lo patients who received myeloablative (MAC)(n = 651), reduced-intensity (RIC)(n = 397), and non-myeloablative conditioning (NMAC) regimens (n = 181). The multivariate analysis revealed that the RIC group had better chronic graft-versus-host disease (GVHD)- and relapse-free survival (CRFS) (P = 0.021), and GVHD- and relapse-free survival (GRFS) than the MAC group (P = 0.001), while no significant differences were observed between the NMAC and MAC groups. In the subgroup analysis, the MAC group has better overall survival (P = 0.008) than the RIC group among patients with an HCT-comorbidity index (HCT-CI) score of 0, while the RIC group had better overall survival (P = 0.029) than the MAC group among those with an HCT-CI score ≥3. According to the type of conditioning regimen, total body irradiation 12 Gy-based MAC regimen showed better OS and CRFS than the other MAC regimen, and comparable outcomes to the RIC regimen. In conclusion, the RIC and NMAC regimens are promising options for MDS-Lo patients in addition to the MAC regimen. |
|
言語 |
en |
| 書誌情報 |
en : Bone Marrow Transplantation
巻 59,
号 8,
p. 1107-1117,
発行日 2024-05-07
|
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0268-3369 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1038/s41409-024-02297-0 |
| 権利 |
|
|
権利情報 |
© 2024, The Author(s), under exclusive licence to Springer Nature Limited. This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1038/s41409-024-02297-0 |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Bone Marrow Transplantation, 59(8), pp.1107-1117; 2024 |
|
言語 |
en |
BMT59_1107.pdf (3.4 MB)
